Health Care·Biotechnology·$10.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.01 | N/A | +80.00% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.01 | N/A | +80.00% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, indicating positive momentum. However, they did not provide specific guidance for future quarters.
The company is pleased with the progress made this quarter.
Management highlighted ongoing developments in their pipeline.
Arrowhead Pharmaceuticals reported a narrower-than-expected loss per share, leading to a positive stock reaction with a 0.96% increase. The company did not disclose revenue figures or future guidance, which leaves some uncertainty for investors. The positive EPS surprise suggests that the company is managing its costs effectively, which may instill some confidence among shareholders.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ROYALTY PHARMA PLC Class A
Aug 9, 2010